Abstract 81P
Background
TRAIL-induced apoptosis pathway is a potential therapeutic target, but the majority of tumors are TRAIL-resistant. TRAIL receptors translocation is associated to TRAIL resistance. Besides TRAIL receptors, DR4 and DR5, other potentially TRAIL-induced apoptosis pathway regulatory proteins are: Apaf-1, CUL3, CLTA (clathrin chain A , involved in TRAIL receptors nuclear translocation) and KPNA-1 ( involved in TRAIL receptors internalization). Overcome TRAIL resistance is essential to therapeutic strategies development.
Methods
A549 cell line was used. Expression of miR-23b, miR-133a, DR4, DR5, Apaf-1, CUL3, CLTA/CLTC and KPNA-1 were estimated by RT-qPCR. Transfection effects of miR-23b inhibitor and Mimic-133a on TRAIL apoptosis pathway components expression. Western Blotting to TRAIL receptors compartmentalization after Mimic-133a and TRAIL stimulus. MTT cell viability assay to evaluate TRAIL-induced cytotoxicity of miR-23b inhibition and Mimic-133a transfection.
Results
A549 was TRAIL resistant. miR-23b was superexpressed and miR-23b inhibition upregulated Apaf-1 and CUL3 expression. miR-133a was undetectable. Mimic-133a transfection downregulated CLTA and DR5 expression. miR-23b inhibition and Mimic-133a transfection promoted TRAIL sensitization.TRAIL receptors were predominantly located in nuclear compartment. Mimic-133a downregulated CLTA expression but did not alter receptors compartmentalization. Mimic-133a and TRAIL associated stimulus leaded to predominant nuclear TRAIL receptors localization in comparison to control cells.
Conclusions
Both miR-23b and -133a are involved in TRAIL cells resistance. Apaf-1 and CUL3 expression downregulation by miR-23b can contribute to resistance. miR-133a role on TRAIL sensitization mechanisms must be further investigated. Mimic-133a downregulated CLTA expression but did not alter TRAIL receptors compartmentalization, suggesting that receptors translocation is clathrin independent.CLTA expression control by miR-133a, however, can contribute to drug-resistance research. Although more research is needed to fully clarify miRs roles on TRAIL-induced apoptosis, our findings deepen TRAIL resistance understanding.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
FAPESP.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
45P - Therapeutic potential of ISM8207: A novel QPCTL inhibitor, in triple-negative breast cancer and B-cell non-Hodgkin lymphoma
Presenter: Sujata Rao
Session: Poster session 09
46P - Effect of coadministration of antioxidant chlorophyllin with docetaxel on invasion and metastasis in triple-negative breast cancer in vivo/in vitro
Presenter: Ayse Burus
Session: Poster session 09
47P - An ozone delivery system by cisplatin prodrug self-assembling micelles combining microwave to sensitizing immune checkpoint inhibitor in triple-negative breast cancer
Presenter: Dan Zheng
Session: Poster session 09
48P - Non-steroid anti-inflammatory treatment enhances the efficacy of modulated electro hyperthermia on triple-negative breast cancer and melanoma cancer models in vivo
Presenter: Nino Giunashvili
Session: Poster session 09
49P - Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer
Presenter: Ana Julia de Freitas
Session: Poster session 09
50P - Application and mechanism of tarloxotinib in HER2-positive breast cancer
Presenter: Xinyi Shao
Session: Poster session 09
51P - Nanoengineered sonosensitive platelets for synergistically augmented sonodynamic breast tumour therapy by glutamine deprivation and cascading thrombosis
Presenter: Liqiang Zhou
Session: Poster session 09
53P - Treatment of cancer cells based on circulating tumor cell’s expression profile using off-label drugs
Presenter: Panagiotis Apostolou
Session: Poster session 09
54P - Enhanced oxidative phosphorylation of metastasis-initiating cells facilitates esophageal tumor cell seeding in lymph nodes
Presenter: Shanshan Li
Session: Poster session 09
55P - Transcriptional profiles of engineered T cells stimulated with different receptor structures and co-stimulatory domains
Presenter: Ungue Shin
Session: Poster session 09